O. Brodin
Uppsala University Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by O. Brodin.
Lung Cancer | 2002
D. Brattström; Michael Bergqvist; Patrik Hesselius; Anders Larsson; Kristina Lamberg; Johan Wernlund; O. Brodin; Gunnar Wagenius
We have analysed the predictive and prognostic information in preoperatively collected serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients clinically evaluated as operable non-small cell lung cancer (NSCLC). Fifty-eight patients with operable NSCLC were included. VEGF and bFGF levels in serum were analysed using enzyme linked immunosorbent assays (Quantikine human VEGF and Quantikine HS human FGF basic, R&D Systems). Univariate analysis demonstrated that tumour volume, platelet counts, VEGF and bFGF were significant prognostic factors. However, only bFGF remained significant in the multivariate analysis (P=0.014). Significant correlations were demonstrated between VEGF levels and tumour volume (r=0.33; P=0.012) and platelet count (r=0.43; P=0.001). bFGF levels correlated significant with recurrent disease (r=0.34; P=0.01), platelet count (r=0.53, P<0.001) and performance status (r=0.29; P=0.029). Furthermore, bFGF levels and VEGF levels correlated significantly (r=0.44; P<0.001). We conclude that elevated circulating angiogenic cytokines correlate with tumour volume, higher relapse risk and poorer survival in patients with operable non-small cell lung cancer.
Lung Cancer | 1997
D. Brattström; Michael Bergqvist; Kristina Lamberg; G. Gustavsson; L. Scheibenflug; Gunnar Wagenius; M. Inganäs; O. Brodin
p53 gene mutations and p53 nuclear immunostaining in non-small cell lung cancer associated with clinical data.
Lung Cancer | 1997
Gunnar Wagenius; M. Berqvist; D. Brattström; Helge Bennmarker; O. Brodin
Palliative radiation with two fractionation schedules of brain metastases from lung cancer.
Lung Cancer | 1997
D. Brattström; Michael Bergqvist; Gunnar Wagenius; O. Brodin
Micronucleos assay as a predictor of radiosensitivity:the results of In Vitro studies on cell lines.
Lung Cancer | 1997
Michael Bergqvist; D. Brattström; L. Lennartsson; Gunnar Wagenius; O. Brodin
BACKGROUND Fluorometric microculture cytotoxicity assay (FMCA) is a short-term semi-automatic method, based on dye-inclusion of surviving cells. The assay was developed for investigations of drug resistance on tumour cells from biopsy material. In the present study, this short-term assay was evaluated, regarding usefulness in determining radio-sensitivity. MATERIALS AND METHODS Eight human lung cancer cell lines were used. There were five small cell lung cancer (SCLC and three non-small cell lung cancer (NSCLC cell lines. Results were compared with the corresponding data derived from the clonogenic assay and/or the extrapolation method. RESULTS The surviving fraction (SF) after 2, 5 and 10 Gy compared with data from the clonogenic assay were not in accordance for 5 of the 8 cell lines. The FMCA assay overestimated SF- values for the SCLC cell lines. CONCLUSION The FMCA assay is not useful as a quick screening method for the radioresponsiveness in vitro of human tumour cell lines.
Anticancer Research | 2001
Ann-Sofi Bergqvist; Michael Bergqvist; Daniel Brattström; Patrik Hesselius; Anders Larsson; O. Brodin; Gunnar Wagenius
Anticancer Research | 2001
Arm-Sofi Bergqvist; Daniel Brattström; Michael Bergqvist; O. Brodin; Gunnar Wagenius; Lilianne Abramsson Zetterberg
Medical Science Monitor | 2004
D. Brattström; Michael Bergqvist; Kenneth Wester; Patrik Hesselius; Zhi-Ping Ren; Lena Scheibenpflug; Gunnar Wagenius; O. Brodin
Lung Cancer | 2005
A. Klinga; Michael Bergqvist; D. Brattström; H. Goike; Patrik Hesselius; O. Brodin; Gunnar Wagenius
Lung Cancer | 2005
Mattias Hedman; D. Brattström; Michael Bergqvist; O. Brodin